Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04006522 · ClinicalTrials.gov registry record · Phase 2

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

A Phase 2 study of Renal Cell Carcinoma, sponsored by James Brugarolas.

Recruiting
Registry status
Phase 2
Development phase
55
Enrollment target
1
Study location

NCT04006522 is a Phase 2 study of Renal Cell Carcinoma that is actively recruiting participants, run by James Brugarolas. The registered enrollment target is 55 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04006522, a Phase 2 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by James Brugarolas.

RECRUITING
Registry status
Phase 2
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of patients with localized RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to nephrectomy and a second cohort of patients with metastatic RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to treatment with an immune checkpoint inhibitor.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • PROCEDURE Positron Emission Tomography/Computed Tomography
  • DRUG 89Zr-DFO-Atezolizumab

Study Locations (1)

Texas

  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2019-10-02
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

James Brugarolas

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04006522

The ClinicalTrials.gov registry entry for NCT04006522 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (77% lower). The listed sponsor is James Brugarolas, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography/Computed Tomography is the first listed.

NCT04006522 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04006522 about?

NCT04006522 is a clinical study titled "89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma". This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-D...

What is the current status of trial NCT04006522?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2019-10-02. Estimated completion is 2026-12-31.

What conditions does trial NCT04006522 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT04006522?

The interventions under investigation include: Positron Emission Tomography/Computed Tomography (PROCEDURE), 89Zr-DFO-Atezolizumab (DRUG).

Who is sponsoring clinical trial NCT04006522?

This trial is sponsored by James Brugarolas, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04006522 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.